Blue Earth Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial Investigating Actinium (²²⁵Ac) rhPSMA-10.1 Injection in Metastatic Castration-Resistant Prostate Cancer

Blue Earth Therapeutics and University College London announced initiation of a Phase I clinical trial evaluating Actinium (225Ac) rhPSMA-10.1 Injection, an investigational alpha‑emitting PSMA‑targeted radiopharmaceutical for the treatment of patients within clinical trials in metastatic CRPC.